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ReviewBiosurfactants have recently emerged as promising
molecules for their structural novelty, versatility, and
diverse properties that are potentially useful for many
therapeutic applications. Mainly due to their surface
activity, these molecules interact with cell membranes
of several organisms and/or with the surrounding envir-
onments, and thus can be viewed as potential cancer
therapeutics or as constituents of drug delivery systems.
Some types of microbial surfactants, such as lipopep-
tides and glycolipids, have been shown to selectively
inhibit the proliferation of cancer cells and to disrupt cell
membranes causing their lysis through apoptosis path-
ways. Moreover, biosurfactants as drug delivery vehicles
offer commercially attractive and scientifically novel
applications. This review covers the current state-of-
the-art in biosurfactant research for therapeutic pur-
poses, providing new directions towards the discovery
and development of molecules with novel structures and
diverse functions for advanced applications.
Biosurfactants as promising molecules
Biosurfactants comprise a group of diverse amphipathic
molecules with distinct chemical structures produced by
several microorganisms. These molecules, which are main-
ly formed as secondary metabolites, play critical roles in
the survival of their producing microorganisms by facili-
tating nutrient transport, interfering in microbe–host
interactions and quorum sensing mechanisms, or by acting
as biocide agents [1]. Their recognized potential and bio-
logical nature has inspired numerous studies on their
possible therapeutic applications (reviewed in [2,3]). These
compounds are superior to synthetic surfactants, owing to
their microbial origin, biodegradability, and low toxicity
[1]. For that reason they have been widely studied for
applications in food and cosmetics industries, enhanced
oil recovery, and bioremediation [1]. They are generally
classified as low (including glycolipids and lipopeptides)
and high molecular weight (polysaccharides, proteins,0165-6147/$ – see front matter
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* These authors contributed equally to this work.lipoproteins, among others) biosurfactants. Generally,
low molecular weight biosurfactants have excellent surface
active properties due to their relatively simpler structures.
Rhamnolipids (glycolipid) (Figure 1A) and surfactin (lipo-
peptide) (Figure 1B) are among the best studied biosurfac-
tants.
Biosurfactants can affect the adhesion of microorganisms
because they partition at interfaces of fluid phases with
distinct polarities and hydrogen bonding [3–5]. Likewise,
these compounds can disrupt cell membranes that lead to
cell lysis by increased membrane permeability and ulti-
mately to leakage of metabolites [6]. Changes in the physical
membrane structure or modifications in protein conforma-
tions occur, thus altering significant membrane functions
that comprise transport and energy generation [4].
Among all properties of biosurfactants, their antibacte-
rial, antifungal, and antiviral activities, in addition to their
anti-adhesive character against pathogens, and probiotic
nature, are the most relevant for health-related applica-
tions [1–3,7]. Some biosurfactants have been reported as
suitable alternatives to synthetic medicines and antimi-
crobials and may be used as safe and effective therapeutic
agents. Their possible applications include gene transfec-
tion, as adjuvants for antigens, as inhibitors of fibrin clot
formation, as activators of fibrin clot lysis, and also as anti-
adhesive coatings for biomaterials, incorporated into pro-
biotic preparations to fight urogenital tract infections and
for pulmonary immunotherapy [8].
Recently, biosurfactants have been shown to have effects
on cancer cells. For instance, the lipopeptide surfactin was
found to induce apoptosis in breast cancer cells [9]. Similar-
ly, the glycolipids mannosylerythritol lipids (MELs) and
succinoyl trehalose lipids (STLs) have been involved in
growth arrest and apoptosis of tumor cells [10–12].
Many other therapeutic applications have been sug-
gested for biosurfactants including novel and attractive
uses in nanotechnology mainly based on their flexible self-
assembling [13]. For example, a liposome vector containing
b-sitosterol b-D-glucoside biosurfactant-complexed DNA
was successfully used for herpes simplex virus thymidine
kinase gene therapy [14]. More recently, nanovectors con-
taining a biosurfactant have been used to increase the
efficacy of gene transfection in vitro and in vivo [15].
Nevertheless, although it seems clear that biosurfac-
tants are valuable, multipurpose, and useful molecules for
therapeutic uses, some may constitute a risk for humans
and should be carefully scrutinized. For example, it isTrends in Pharmacological Sciences xx (2013) 1–9 1
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Figure 1. Chemical structure of common biosurfactants: rhamnolipid (A) and
surfactin (B).
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severe nosocomial infections, yet this strain produces pow-
erful glycolipids for several medical-related applications
[16,17].
This review discusses the current state of biosurfactant
research, with an emphasis on potential therapeutic appli-
cations. We aim to provide new insights and directions
towards discovering molecules with novel structures and
diverse functions for cutting edge applications as improved
anticancer drugs or nanoscale microemulsion-based drug
delivery vectors.
Biosurfactants as antitumor agents
One of the most exciting findings that has been reported for
biosurfactants is their ability to control a variety of mam-
malian cell functions and therefore their potential to act as
antitumor agents interfering with some cancer progression
processes (Table 1). Indeed, these molecules have been
shown to participate in several intercellular molecular
recognition steps such as signal transduction, cell differ-
entiation, and cell immune response, among others [8].
For example, glycolipids (amphipathic molecules con-
sisting of lipids with a carbohydrate attached) have been
shown to be involved in growth arrest and apoptosis of
mouse malignant melanoma B16 cells. Exposure to in-
creasing concentrations of MELs led to the accumulation
of B16 cells in the sub-G0/G1 phase, which is a sign of cells
undergoing apoptosis. Furthermore, a sequence of apopto-
tic events was observed including the condensation of
chromatin and DNA fragmentation, thus confirming the
apoptosis-inducing potential of MELs in these cells [10].2This report suggests that regulation of the activity of
protein kinase C (PKC) might be associated with apoptosis
induced by MELs. Activation of PKC is one of the first
events in the signal transduction that leads to a multiplic-
ity of cellular responses. Indeed, members of the PKC
family are key factors in cell differentiation, control of
growth, and cell death. Additionally, MELs have been
shown to induce the differentiation of human promyelocy-
tic leukemia HL60 cells towards granulocytes [18].
MELs were found to markedly increase common differen-
tiation-associated characteristics in granulocytes, such
as nitroblue tetrazolium reducing ability, expression of
Fc receptors (Fc – surface immunoglobulin molecule)
and phagocytic activities in HL60 cells. Furthermore,
the authors demonstrated that MELs inhibited the activity
of PKC in these cells. Their results suggest that the
differentiation-inducing activity of MELs might involve
changes in membrane-associated molecules. The above-
mentioned reports indicate that MEL biosurfactants can
trigger both apoptotic and differentiation mechanisms
[10,18]. In other studies, MELs have also shown excellent
growth inhibition and differentiation activities against
several cancer cell lines [11,19–21]. Likewise, STLs have
also been shown to inhibit growth and induce differentia-
tion of human leukemia cells [18,22].
Additionally, sophorolipids have been found to trigger
cell differentiation instead of cell proliferation and to
inhibit PKC activity in the HL60 human leukemia cell
line. This activity is not caused by a simple detergent-like
effect but is attributed to a specific interaction with the
plasma membrane [12]. The sophorolipid produced by
Wickerhamiella domercqiae was shown to induce apoptosis
in H7402 human liver cancer cells by blocking the cell cycle
at G1 phase, activating caspase-3, and increasing Ca2+
concentration in the cytoplasm [23]. Fu and collaborators
[24] investigated the effects of different sophorolipid deri-
vatives against human pancreatic carcinoma cells and
demonstrated that the cytotoxic effect was dependent on
the derivative (the methyl ester derivative being the most
effective), suggesting that distinct mechanisms may be
involved in this effect. Similarly, Shao and collaborators
[25] investigated the effect of sophorolipid molecules with
different structures on human esophageal cancer cell lines.
Stronger inhibition was shown for sophorolipids with
higher degrees of acetylation, (specifically, 30 mg/ml of
diacetylated lactonic sophorolipid completely inhibited
cells), whereas twice the concentration was necessary to
obtain the same inhibitory effect with monoacetylated
lactonic sophorolipid. The sophorolipid with one double
bond in the fatty acid part had the strongest cytotoxic
effect, whereas the antitumor activity of acidic sophoroli-
pids was scarce. The authors put forward that different
mechanisms may be involved in the anticancer activities
observed for the different sophorolipid derivatives [24,25].
Nevertheless, these studies only evaluate the cytotoxicity
of these compounds and do not deeply investigate the
possible mechanisms underlying such activity. Notwith-
standing, because different sophorolipid derivatives
were found to exhibit different anticancer activities, these
findings suggest that a rational manipulation of the
sophorolipid structures, namely with higher acetylation
Table 1. Biosurfactants with antitumor activity against human cancer cells
Biosurfactant Cell line Description Activity Refs
Mannosylerythritol
lipids (MELs)
K562 Myelogenous leukemia Growth inhibition, differentiation [11]
Succinoyl trehalose
lipids (STLs)
HL60 Promyelocytic leukemia Growth inhibition, differentiation [22]
KU812 Basophilic leukemia Growth inhibition [12]
Sophorolipids HL60 Promyelocytic leukemia Interaction with plasma membrane [18]
H7402 Liver cancer Growth inhibition, cell cycle arrest,
apoptosis induction
[23]
A549 Lung cancer Apoptosis induction [23]
HPAC Pancreatic cancer Necrosis [24]
KYSE109/KYSE450 Esophageal cancer Growth inhibition [25]
Surfactin or surfactin-like
biosurfactants
BEL7402 Hepatocellular carcinoma Growth inhibition, apoptosis induction [32]
K562 Myelogenous leukemia Growth inhibition, cell cycle arrest,
apoptosis induction
[32,35]
LoVo Colon adenocarcinoma Growth inhibition, apoptosis induction [28]
MCF7 Breast cancer Growth inhibition, apoptosis induction [9,29,30]
T47D/MDA-MB231 Breast cancer Growth inhibition, cell cycle arrest Unpublished
data
Caco2 Colorectal cancer Growth inhibition, apoptosis induction [33]
HCT15/HT29 Colon cancer Growth inhibition [27]
e-poly-L-lysine HeLaS3 Cervix adenocarcinoma Growth inhibition [34]
HepG2 Hepatocellular liver carcinoma Growth inhibition [34]
Viscosin PC3M Metastatic prostate cancer Migration inhibition [36]
Serratamolide BCLL B-Chronic lymphocytic leukemia Apoptosis induction [37]
Monoolein HeLa Cervical cancer Growth inhibition [39]
U937 Leukemia cancer Growth inhibition [39]
Glycoprotein from
Lactobacillus paracasei
T47D/MDA-MB231 Breast cancer Growth inhibition, cell cycle arrest Unpublished
data
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fatty acid, and lactonization, may lead to novel compounds
with improved performances.
Other less studied glycolipids have also been reported
for their potential antitumor promoting activity, for exam-
ple, the crude glycolipid from Sphingobacterium detergens
against Caco2 human colorectal cancer cells [26].
Lipopeptides, including surfactin, have also been widely
studied for their potential antitumor activity against sev-
eral cancer cell lines [27]. Kim and collaborators [28]
showed that surfactin blocks cell proliferation by inducing
proapoptotic activity and arresting the cell cycle.
Furthermore, surfactin strongly blocked the PI3K/Akt
signaling pathway [PI3K – phosphoinositide 3 kinase; Akt
also known as protein kinase B (PKB) is a serine/threo-
nine-specific protein kinase; both proteins are involved in
multiple cellular processes such as cell proliferation and
apoptosis]. This pathway is known to play a central role in
regulating proapoptotic processes including cell cycle ar-
rest. Altogether, these results suggest that surfactin can
downregulate the cell cycle and suppress cancer cell sur-
vival. In addition, surfactin purified from the strain Bacil-
lus subtilis CSY191 (probiotic strain) was found to inhibit
the growth of MCF7 human breast cancer cells in a dose-
dependent manner [29]. Cao and collaborators [9] further
demonstrated that this lipopeptide induces apoptosis
in MCF7 cells through a reactive oxygen species/c-Jun
N-terminal kinase (ROS/JNK)-mediated mitochondrial/
caspase pathway. In addition, the authors showed that
surfactin induces ROS formation, leading to mitochondrial
permeability and membrane potential collapse that ulti-
mately results in an increase of ion calcium concentrationin the cytoplasm [30]. Afterwards, cytochrome c released
from mitochondria to the cytoplasm activates caspase-9,
eventually inducing apoptosis. Moreover, surfactin was
shown to inhibit the proliferation of MCF7 cells through
cell arrest at the G2/M phase [31]. Indeed, surfactin induced
accumulation of the tumor suppressor p53 and cyclin kinase
inhibitor p21waf1/cip1, and inhibited the activity of the G2-
specific kinase, cyclin B1/p34cdc2. These findings suggest
that surfactin caused the G2/M arrest of MCF7 cells through
the regulation of their cell cycle factors. The same research
group demonstrated the cytotoxic effect of surfactin, in a
dose-dependent manner, against the human chronic mye-
logenous leukemia cells K562 and the hepatic carcinoma
cells BEL7402 [32]. Wang et al. [33] also demonstrated that
surfactin induces apoptosis in HepG2 cells through ROS–
endoplasmic reticulum stress (ERS)–Ca2+–extracellular
signal-regulated protein kinase (ERK) pathways. A summa-
ry of the proposed mechanisms underlying the anticancer
effect of surfactin is illustrated in Figure 2.
Different lipopeptides produced by Bacillus, Pseudomo-
nas, and Serratia species have also exhibited antitumoral
activity against various human cancer cells [27,34–38].
Because there is an enormous diversity of microbial
surfactants, new molecules with interesting antitumor
activities are continuously being reported. This is the case
of the biosurfactant monoolein produced by the dematiac-
eous fungus Exophiala dermatitidis SK80 [39]. The bio-
surfactant effectively inhibited the proliferation of cervical
cancer (HeLa) and leukemia (U937) cell lines in a dose-
dependent manner. Interestingly, no cytotoxicity was
found with normal cells, even when high concentrations
were used. Cell and DNA morphological changes observed3
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Figure 2. Proposed mechanisms involved in the antitumoral activity of surfactin. Abbreviations: AIF, apoptosis-inducing factor; Cyt c, cytochrome c; ERK, extracellular
signal-regulated protein kinase; JNK, c-Jun N-terminal kinase; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species.
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blebbing, and DNA fragmentation. Another example is the
glycoprotein produced by Lactobacillus paracasei [40] that
is active against human breast cancer cells.
Although researchers have been reporting the antitu-
mor potential of biosurfactants, few studies have investi-
gated the mechanisms involved in such activity. Indeed,
most studies use a single cancer cell line to assess the
cytotoxicity of the biosurfactants without using proper
controls (e.g., normal cell lines), which means that these
compounds may not be as specific as desired, and by
contrast may be only effective against that single cell line.
Also, some of these studies are somewhat preliminary and
support their conclusions in a simple assessment of cell
viability using a single method. Furthermore, although
some results seem very promising, they are based on cell
lines and further in vivo experiments must be conducted in
order to validate the potential of the compounds. The
shortcoming of most studies on the anticancer potential
of biosurfactants is undoubtedly the lack of detail concern-
ing the mechanisms that underlie the activity of these
compounds.
Biosurfactants have been implicated in several intercel-
lular molecular recognition steps through interference
with specific molecules. For example, it has been reported
that the profiles of lipids in normal and cancerous tissues
differ, such as the cell membrane lipids [41–45]. Because4lipids are surface active, any change in lipid profiles can
lead to altered surface activity profiles. These membrane
lipids can, however, interact with biosurfactants. The in-
teraction between these two surface active molecules can
lead to important cell membrane modifications and ulti-
mately to cell death. Lipid composition determines the
structure, function, and integrity of biological membranes,
and phosphatidylcholine (PC) and sphingomyelin (SM), in
particular, play a role in stabilizing the bilayer structure.
Preetha and collaborators [41] demonstrated that the
phospholipid profiles of normal and cancerous cervical
tissues were significantly different, namely, that the PC
levels in cancer tissue were nearly 5-fold higher than those
in normal tissue. PC and SM were found to be the major
phospholipid components in cancerous and normal cervical
tissues, respectively. The authors suggest that changes in
membrane fluidity, due to PC and SM levels (these phos-
pholipids confer rigidity to the membrane), in turn might
affect the permeability of the cancer cell membranes.
Therefore, new therapeutic strategies may be designed,
considering that the use of biosurfactants can alter lipid
content (specifically PC and SM), to fluidize rigid cancerous
tissues and to modulate interfacial properties. The in-
creased rigidity manifests as a lower surface tension and
can reduce the penetration of drugs through such mem-
branes. The role of fluidizers in reversing these rigidifying
effects and improving drug penetration in cancerous
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open interesting perspectives for the development of drug
carriers based on surface active molecules, such as biosur-
factants, that can interact with cell membrane lipids, or for
the design of agents that can interact with other lipids
involved in several cellular processes. For instance, bio-
surfactants could be used to influence the activity of
sphingolipids, because these lipids emerged as effector
molecules, which control various aspects of cell growth,
proliferation, and anticancer therapeutics [46].
Finally, the ability of biosurfactants to disrupt cell
membranes, leading to a sequence of events that include
lysis, increased membrane permeability, and metabolite
leakage, has also been suggested as a probable mechanism
of antitumor activity [47].
Biosurfactants as drug delivery agents
The discovery of new drugs and novel drug delivery sys-
tems (DDSs) with improved efficacies has made a signifi-
cant impact on our ability to treat many types of diseases
[48]. Ideally, a controlled DDS should hold two important
characteristics: (i) optimal drug loading capacity, which
leads to increased bioavailability of drug and ability to
reach the target of interest, and (ii) the subsequent release
of the drug in a controlled and phased manner. To accom-
plish these two essential purposes, different types of
pharmaceutical carriers such as polymeric, particulate,
macromolecular, and cellular carriers have been tested
and are currently used. Of these, the particulate type exists
in a dispersed colloidal form with structures that include
microspheres, nanoparticles, lipid particles, micelles, and
vesicular systems such as liposomes, noisome, virosomes,
and sphingosomes [49]. Microemulsions have emerged as
novel DDSs suitable for transdermal, topical, oral, nasal,
ocular, intravenous, parenteral, and other routes of drug
administration (reviewed in [48]). They have been the focus
of significant attention of researchers owing to their easi-
ness in formulation. However, systematic and preclinical
studies are required before an optimal formulation can
guarantee the safety and efficacy criteria for a given route
of drug administration. Because microemulsion systems
are thermodynamically stable [50], more caution has been
particularly used in the formulation of self-microemulsify-
ing drug delivery systems (SMEDDSs) for oral or paren-
teral routes. It is important to note that most DDSs fail
when these routes of administration are used [51]. Several
reasons have been reported for DDS failure, ranging from
poor efficacy in delivering the drug to the drug precipita-
tion due to dilution by biological fluids before reaching the
target site. However, the important criterion that most
formulations fail to abide is the judicious use of biocom-
patible and biodegradable pharmaceutical agents as their
ingredients.
Microemulsion
A microemulsion-based colloidal DDS generally comprises
an aqueous phase (usually water), an oil phase, a surfactant,
and often includes a co-surfactant or co-solvent. The surfac-
tant, which is the principal ingredient of a microemulsion
system, self-aggregates to form templates of varying
structures. These structures can encapsulate/solubilizea hydrophobic or hydrophilic drug in the presence of a
dispersed phase [oil in the case of oil-in-water (O/W) and
water in the case of water-in-oil (W/O) microemulsions]
within its structural core (spherical in most cases),
thereby partitioning the dispersed phase from the con-
tinuous phase [52]. Typically, a global microemulsion
system exhibits a wide range of structures of distinct
nanometric-scaled geometries (e.g., worm-like, bicontin-
uous sponge-like, liquid crystalline, or hexagonal, spher-
ical swollen micelles) involving the formation of one, two,
or even three phases. Furthermore, the thermodynamic
dependency of these microemulsion systems clearly sug-
gests that any change in the composition and tempera-
ture of the system will cause phase separation and lead
to eventual loss of the emulsified drug.
Green molecules in drug formulation
In recent years, formulators have been actively seeking
pharmaceutically acceptable excipients to design safer
microemulsions. Previous efforts have typically used syn-
thetic hydrocarbon oils such as heptanes, dodecane, and
cyclic oils such as cyclohexane, and surfactants with 12
carbon hydrophobic chains such as sodium dodecyl sulfate
and tetraethylene glycol monododecyl ether, which are not
approved for use in pharmaceutical formulations, and can
present biocompatibility issues and exhibit some toxic
effects [53]. To a reasonable extent, biocompatibility has
been guaranteed through the use of lecithins and non-ionic
surfactants such as Brijs, Arlacel 186, Spans, Tweens, and
AOT, which are amphiphiles (components of microemul-
sion systems) that have been widely demonstrated to
exhibit a high biocompatibility [54]. At the same time, it
is encouraging to see a recent tendency to use natural oils
as alternatives for synthetic oils and surfactants to formu-
late nontoxic pharmaceutically acceptable microemulsion
systems. Vegetable oils have been the focus of huge inter-
est, but it is relatively difficult to solubilize them in micro-
emulsions [55]. Similarly, natural surfactants have
emerged as potential alternatives for their synthetic coun-
terparts. In particular, non-ionic surfactants such as su-
crose esters, containing a hydrophilic sucrose group and
fatty acid chains of varying degrees as a lipophilic group,
have been widely employed in microemulsion formulation
[56,57].
Biosurfactants have emerged as a better alternative to
their synthetic counterparts. The recent trend in their use
as templates for nanoparticle synthesis indicates the con-
stantly increasing potential of biosurfactants to serve as
greener alternatives to their synthetic counterparts [58].
Challenges, selection guidelines, and future prospects of
biosurfactants in drug delivery applications
Although it is very difficult to predict the nature and
stability of a microemulsion-based DDS, data reported
in the literature can drive the selection of the most appro-
priate oil/biosurfactant system. Environmental conditions
can strongly affect some biosurfactants and consequently
their self-assembly. Regarding rhamnolipids and surfac-
tin, adequate results are available pertaining to their
structural aspects at different interfaces and solutions,
as described below [59–62]. However, these molecules,5
(I)
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Increasing salinity (ionic surfactants)
Water Oil Microemulsion
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Figure 3. Winsor classification of microemulsions. Microemulsions can exist in
three forms, known as Winsor type microemulsions. Type I (O/W), when the water–
surfactant interaction is stronger than oil–surfactant interaction (R < 1),
microemulsions solubilize oil in spherical normal micelles within the water-
continuous phase. Type II (W/O), when the strength of oil–surfactant interaction is
stronger than water–surfactant interaction (R > 1), microemulsions solubilize
water in reverse micelles within the oil-continuous phase. Type III, when the
interactions are balanced (R = 1); in this case, microemulsions are three-phase
systems in which the middle phase microemulsions are in equilibrium with both
excess oil and excess water phases.
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cations between their hydrophilic and lipophilic groups.
The very complex nature of the head groups (e.g., amino
acids in lipopeptide and saccharides in glycolipids) further
complicates proper assessment of their structure, because
they can adopt varied structures with only a slight change
in the environment. This behavior is linked to the presence
of one and two carboxylic acids in di-rhamnolipids and
surfactin, respectively.
Generally, it can be assumed that these biosurfactants
are anionic at high pH values (due to the presence of
carboxylic groups) and non-ionic at low pH values [63].
Also, structure transition from micellar to lamellar upon
electrolyte addition has been reported [64,65]. Such possi-
bility of manipulating structure transition may be of great
interest to tailor a DDS for a given drug, or to confer its
functionality in particular environmental conditions (con-
trolled drug release), for example, triggered by pH, tem-
perature, or salt concentrations [66]. Aggregation of
surfactants in a lamellar arrangement can occur if one
of the following requirements is met. High surfactant
concentrations in water often lead to a lyotropic lamellar
liquid crystalline phase. Double-tailed amphiphiles com-
monly form bilayer sheets, because their most hydrated
state enables the molecules to pack only in a lamellar
arrangement. Upon closing, these sheets form vesicles.
Lamellar aggregates can also be formed from mixtures
of anionic and cationic surfactants in water, mixtures of
ionic surfactants and long-chain alcohols in water, or
electrolyte solution. As previously mentioned, some sur-
factant molecules in aqueous solution are spontaneously
transformed from micelles into a lamellar arrangement in
the presence of a high salt concentration. This change
in aggregate morphology is facilitated by an increase in
counter ion binding and dehydration of the surfactant head
groups and bound counter ions. On a larger scale, inter-
actions between lamellae occur, leading to the formation of
either unilamellar vesicles or multilayered systems. Owing
to the lack of systematic studies on the characteristics of
biosurfactant microemulsion systems, such as phase be-
havior and its stability under different physicochemical
conditions and compatibility of oil and co-surfactants, drug
delivery applications of biosurfactants remain to be devel-
oped. However, it is strongly believed that prior knowledge
about the characteristics of the system and its components
through a proper assessment of various parameters such
as the hydrophilic–lypophilic balance (HLB), critical pack-
ing parameter (CPP), and Winsor R ratio would signifi-
cantly reduce the complexity of a rational choice of
components that ultimately lead to a successful micro-
emulsion formulation. Furthermore, these parameters
can guide researchers in designing more realistic drug
formulations for a specific route of administration. The
HLB affects the stability of the emulsion and represents
the relative contribution of hydrophilic and lipophilic
groups of the surfactant. As a general rule, low HLB values
(3–6) favor the formation of W/O microemulsions, whereas
high HLB values (8–18) favor O/W microemulsions. For
surfactants with very high HLB values (>20), often a co-
surfactant is required to reduce their effective HLB value.
Amphiphilic molecules exhibit a broad and puzzling phase6behavior and offer interesting technical challenges regard-
ing their application in DDSs. These molecules spontane-
ously self-assemble into a wide variety of structures,
including spherical (surfactin) and cylindrical (rhamnoli-
pids) micelles, which depend on several environmental
conditions. The CPP provides an idea on the ability of a
surfactant to form aggregates corresponding to their own
geometries. The Winsor R parameter represents the ratio
of the total interaction energies (per unit area of interface)
of the surfactant for the O and W phases and is also
dependent on environmental factors (Figure 3).
Some of the most relevant properties of surfactin and
di-rhamnolipids for the formulation of microemulsions are
summarized in Table 2. The HLB and CPP values suggest
that these two biosurfactants are able to form O/W
microemulsions, provided that alkaline conditions are
maintained. High surface activities imply that only rela-
tively low quantities of these biosurfactants are required to
formulate a microemulsion for drug delivery. Furthermore,
the high HLB value in the case of rhamnolipids indicates
that a co-surfactant may often be required to alter the HLB
value leading to microemulsion formation. Xie et al. [63]
studied the effect of different alcohols (three to eight
carbons) as co-surfactants on the microemulsion phase
behavior (rhamnolipid/n-heptane/water system). Addition
of alkali favorably changed the hydrophobic nature of
rhamnolipids at low pH to a hydrophilic anionic surfactant.
This study showed that excess of sodium ions influenced
the phase behavior of the system by minimizing
Table 2. Important properties guiding biosurfactant selection for microemulsion formulation
Biosurfactant cmc (mM)/surface
tension (mN/m)
Mw (Da) HLB CPP
b Comments
Experimentala Empirical Experimental
Surfactin 20/27.2 1035 10–12 0.1435 – HLB indicates favoring O/W microemulsion
CPP (<1/3) indicates favoring spherical
micelles
Di-rhamnolipid 110/29.0 650 22–24 0.38 0.5 HLB indicates favoring O/W microemulsion
CPP (<0.5) indicates favoring mesophase
of cylinders
aFor surfactin, it is only a suggestive value based on its ability to reduce surface tension to 27.2 mN/m.
bArea for empirical CPP calculation is considered as 147 A˚2 for surfactin [62] and 80 A˚2 for rhamnolipid [59].
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Because the rhamnolipid displayed strong affinity towards
water, only Winsor type I microemulsion could be obtained.
Moreover, it was reported that increasing the chain length
of the alcohol reduced the phase existence area of a two-
phase microemulsion system, and also that the phase
existence region of the single phase microemulsion was
maximum for n-butanol. These results suggest that bio-
surfactants are suitable for emergent drug delivery appli-
cations. Nguyen and Sabatini [67] used rhamnolipids as a
co-surfactant to alter the HLB value of methyl ester ethox-
ylate, a biorenewable surfactant, to form a microemulsion
with the limonene O/W system, and oleyl alcohol was used
as a hydrophilic linker.
Recently, Onaizi et al. [68] studied the micellization and
interfacial behavior of a mixture of surfactin and sodium
dodecylbenzylsulfonate, showing that the formation of
mixed micelles was thermodynamically feasible. Owing
to the previously mentioned biosurfactant features, mixed
biosurfactant–synthetic surfactant systems are advanta-
geous because they represent greener and sustainable
formulations compared with conventional systems. Fur-
thermore, these mixed systems may reduce the costs as-
sociated with the exclusive use of biosurfactants and
could also encourage the development of a more efficient
mixture.
In a separate study, the glycolipid MEL-A synthesized
by Pseudozyma antarctica was used to investigate the
phase behavior of a ternary MEL-A/water/n-decane system
[69]. The MEL-A-stabilized system formed a W/O micro-
emulsion without the need for co-surfactants. Nguyen et al.
[70] successfully formulated the most broadly studied bio-
compatible lecithin-based microemulsion in combination
with rhamnolipid and sophorolipid biosurfactants. These
microemulsions showed remarkable stability for tempera-
tures up to 408C and an electrolyte concentration of 4%
(w/v), thus making them suitable for cosmetic and drug
delivery applications. Taking a cue from these develop-
ments, microemulsions can be designed based on a cau-
tious combination of an oil phase and a suitable
biosurfactant.
Biosurfactants, in addition to their imminent potential
for application in microemulsion-based drug formulations,
have also been reported for use in triggered and targeted
drug delivery. Shim et al. [71] successfully demonstrated
the enhanced delivery of small interfering RNA (siRNA) in
HeLa cells using cationic surfactin liposomes when com-
pared with surfactin-free liposomes. This study also indi-
cated that surfactin-containing liposomes with theirhigher biocompatibility may improve the specific silencing
of the gene of interest, that is, a more efficient delivery
system led to an increase of the cellular uptake of siRNA,
thus increasing the specific knockdown effect. In a recent
study, Cheow and Hadinoto [72] evaluated the rhamnoli-
pids from P. aeruginosa biofilm for their ability to trigger
the release of a drug encapsulated in lipid–polymer coated
hybrid nanoparticles. In such a way, it was possible to
trigger the drug release in the vicinity of the P. aeruginosa
colonies, thus improving the antibacterial effectiveness of
those nanoparticles. Although these studies were aimed for
rhamnolipid triggered drug release by P. aeruginosa bio-
film cultures embedded in expectoration under in vivo
conditions, the concept of targeted and triggered drug
release using biosurfactants can be further applied to
the development of DDSs.
Concluding remarks
Lipopeptide, glycolipid, and other types of biosurfactants,
owing to their structural novelty and diverse biophysical
properties, have recently emerged as possible broad-
spectrum agents for cancer chemotherapy/biotherapy
and as safe vehicles or ingredients in drug delivery for-
mulations. Many new applications of these biomolecules
have been suggested, mainly owing to their significant
surface active properties that enable them to interact with
cell membranes or surrounding environments to bring
about the desired effect as a therapeutic molecule or as
a part of a DDS. The search for safe and biocompatible
biosurfactants for such applications will drive this field of
research in the coming years. The abilities of these mole-
cules to selectively inhibit the proliferation of cancer cell
lines and disrupt cell membranes causing cellular lysis by
operating apoptotic machineries may provide the clues for
the mechanism and mode of their actions. A better under-
standing of the underpinning principles vis-a`-vis the mech-
anisms of actions at the molecular level would prompt
researchers to develop a blueprint of the internal proceed-
ings that can guide in conducting preclinical studies and
clinical trials at a later stage.
Drug delivery is another promising area wherein bio-
surfactants can find potential therapeutic application.
Despite the ever increasing demand of biosurfactants for
commercial applications, their use in drug delivery
requires further research on the interactions between
the different components in microemulsions. Limited
reports addressing safety issues on the use of biosurfac-
tants as adjuvants in microemulsion formulations are
available. Moreover, hemolytic activity of most of the7
Review Trends in Pharmacological Sciences xxx xxxx, Vol. xxx, No. x
TIPS-1092; No. of Pages 9reported biosurfactants and the scarcity of clinical data on
the use and validation of such molecules in animal models
and human volunteers pose a major challenge in preparing
safe drug delivery formulations. Nevertheless, some bio-
surfactants have proven their efficacy in cosmetic and
antibiotic formulations and additionally fulfilled the
requirements of the drug regulatory bodies worldwide
for biocompatible and nontoxic excipients, thus paving
the way for the successful implementation of these
molecules in drug delivery formulations.
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